Radiation biology and oncology in the genomic era

Sarah L. Kerns, Kuang Hsiang Chuang, William Hall, Zachary Werner, Yuhchyau Chen, Harry Ostrer, Catharine West, Barry Rosenstein

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Radiobiology research is building the foundation for applying genomics in precision radiation oncology. Advances in high-throughput approaches will underpin increased understanding of radiosensitivity and the development of future predictive assays for clinical application. There is an established contribution of genetics as a risk factor for radiotherapy side effects. An individual's radiosensitivity is an inherited polygenic trait with an architecture that includes rare mutations in a few genes that confer large effects and common variants in many genes with small effects. Current thinking is that some will be tissue specific, and future tests will be tailored to the normal tissues at risk. The relationship between normal and tumor cell radiosensitivity is poorly understood. Data are emerging suggesting interplay between germline genetic variation and epigenetic modification with growing evidence that changes in DNA methylation regulate the radiosensitivity of cancer cells and histone acetyltransferase inhibitors have radiosensitizing effects. Changes in histone methylation can also impair DNA damage response signaling and alter radiosensitivity. An important effort to advance radiobiology in the genomic era was establishment of the Radiogenomics Consortium to enable the creation of the large radiotherapy cohorts required to exploit advances in genomics. To address challenges in harmonizing data from multiple cohorts, the consortium established the REQUITE project to collect standardized data and genotyping for ∼5,000 patients. The collection of detailed dosimetric data is important to produce validated multivariable models. Continued efforts will identify new genes that impact on radiosensitivity to generate new knowledge on toxicity patho-genesis and tests to incorporate into the clinical decision-making process.

Original languageEnglish (US)
Article number20170949
JournalBritish Journal of Radiology
Volume91
Issue number1091
DOIs
StatePublished - Jan 1 2018

Fingerprint

Radiobiology
Radiation Oncology
Radiation Tolerance
Genomics
Radiotherapy
Multifactorial Inheritance
Radiation-Sensitizing Agents
Genes
Histone Acetyltransferases
DNA Methylation
Epigenomics
Histones
Methylation
DNA Damage
Neoplasms
Mutation
Research

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kerns, S. L., Chuang, K. H., Hall, W., Werner, Z., Chen, Y., Ostrer, H., ... Rosenstein, B. (2018). Radiation biology and oncology in the genomic era. British Journal of Radiology, 91(1091), [20170949]. https://doi.org/10.1259/bjr.20170949

Radiation biology and oncology in the genomic era. / Kerns, Sarah L.; Chuang, Kuang Hsiang; Hall, William; Werner, Zachary; Chen, Yuhchyau; Ostrer, Harry; West, Catharine; Rosenstein, Barry.

In: British Journal of Radiology, Vol. 91, No. 1091, 20170949, 01.01.2018.

Research output: Contribution to journalReview article

Kerns, SL, Chuang, KH, Hall, W, Werner, Z, Chen, Y, Ostrer, H, West, C & Rosenstein, B 2018, 'Radiation biology and oncology in the genomic era', British Journal of Radiology, vol. 91, no. 1091, 20170949. https://doi.org/10.1259/bjr.20170949
Kerns SL, Chuang KH, Hall W, Werner Z, Chen Y, Ostrer H et al. Radiation biology and oncology in the genomic era. British Journal of Radiology. 2018 Jan 1;91(1091). 20170949. https://doi.org/10.1259/bjr.20170949
Kerns, Sarah L. ; Chuang, Kuang Hsiang ; Hall, William ; Werner, Zachary ; Chen, Yuhchyau ; Ostrer, Harry ; West, Catharine ; Rosenstein, Barry. / Radiation biology and oncology in the genomic era. In: British Journal of Radiology. 2018 ; Vol. 91, No. 1091.
@article{dff0be0bb9004bbf9000e2c4ce8b2ffe,
title = "Radiation biology and oncology in the genomic era",
abstract = "Radiobiology research is building the foundation for applying genomics in precision radiation oncology. Advances in high-throughput approaches will underpin increased understanding of radiosensitivity and the development of future predictive assays for clinical application. There is an established contribution of genetics as a risk factor for radiotherapy side effects. An individual's radiosensitivity is an inherited polygenic trait with an architecture that includes rare mutations in a few genes that confer large effects and common variants in many genes with small effects. Current thinking is that some will be tissue specific, and future tests will be tailored to the normal tissues at risk. The relationship between normal and tumor cell radiosensitivity is poorly understood. Data are emerging suggesting interplay between germline genetic variation and epigenetic modification with growing evidence that changes in DNA methylation regulate the radiosensitivity of cancer cells and histone acetyltransferase inhibitors have radiosensitizing effects. Changes in histone methylation can also impair DNA damage response signaling and alter radiosensitivity. An important effort to advance radiobiology in the genomic era was establishment of the Radiogenomics Consortium to enable the creation of the large radiotherapy cohorts required to exploit advances in genomics. To address challenges in harmonizing data from multiple cohorts, the consortium established the REQUITE project to collect standardized data and genotyping for ∼5,000 patients. The collection of detailed dosimetric data is important to produce validated multivariable models. Continued efforts will identify new genes that impact on radiosensitivity to generate new knowledge on toxicity patho-genesis and tests to incorporate into the clinical decision-making process.",
author = "Kerns, {Sarah L.} and Chuang, {Kuang Hsiang} and William Hall and Zachary Werner and Yuhchyau Chen and Harry Ostrer and Catharine West and Barry Rosenstein",
year = "2018",
month = "1",
day = "1",
doi = "10.1259/bjr.20170949",
language = "English (US)",
volume = "91",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1091",

}

TY - JOUR

T1 - Radiation biology and oncology in the genomic era

AU - Kerns, Sarah L.

AU - Chuang, Kuang Hsiang

AU - Hall, William

AU - Werner, Zachary

AU - Chen, Yuhchyau

AU - Ostrer, Harry

AU - West, Catharine

AU - Rosenstein, Barry

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Radiobiology research is building the foundation for applying genomics in precision radiation oncology. Advances in high-throughput approaches will underpin increased understanding of radiosensitivity and the development of future predictive assays for clinical application. There is an established contribution of genetics as a risk factor for radiotherapy side effects. An individual's radiosensitivity is an inherited polygenic trait with an architecture that includes rare mutations in a few genes that confer large effects and common variants in many genes with small effects. Current thinking is that some will be tissue specific, and future tests will be tailored to the normal tissues at risk. The relationship between normal and tumor cell radiosensitivity is poorly understood. Data are emerging suggesting interplay between germline genetic variation and epigenetic modification with growing evidence that changes in DNA methylation regulate the radiosensitivity of cancer cells and histone acetyltransferase inhibitors have radiosensitizing effects. Changes in histone methylation can also impair DNA damage response signaling and alter radiosensitivity. An important effort to advance radiobiology in the genomic era was establishment of the Radiogenomics Consortium to enable the creation of the large radiotherapy cohorts required to exploit advances in genomics. To address challenges in harmonizing data from multiple cohorts, the consortium established the REQUITE project to collect standardized data and genotyping for ∼5,000 patients. The collection of detailed dosimetric data is important to produce validated multivariable models. Continued efforts will identify new genes that impact on radiosensitivity to generate new knowledge on toxicity patho-genesis and tests to incorporate into the clinical decision-making process.

AB - Radiobiology research is building the foundation for applying genomics in precision radiation oncology. Advances in high-throughput approaches will underpin increased understanding of radiosensitivity and the development of future predictive assays for clinical application. There is an established contribution of genetics as a risk factor for radiotherapy side effects. An individual's radiosensitivity is an inherited polygenic trait with an architecture that includes rare mutations in a few genes that confer large effects and common variants in many genes with small effects. Current thinking is that some will be tissue specific, and future tests will be tailored to the normal tissues at risk. The relationship between normal and tumor cell radiosensitivity is poorly understood. Data are emerging suggesting interplay between germline genetic variation and epigenetic modification with growing evidence that changes in DNA methylation regulate the radiosensitivity of cancer cells and histone acetyltransferase inhibitors have radiosensitizing effects. Changes in histone methylation can also impair DNA damage response signaling and alter radiosensitivity. An important effort to advance radiobiology in the genomic era was establishment of the Radiogenomics Consortium to enable the creation of the large radiotherapy cohorts required to exploit advances in genomics. To address challenges in harmonizing data from multiple cohorts, the consortium established the REQUITE project to collect standardized data and genotyping for ∼5,000 patients. The collection of detailed dosimetric data is important to produce validated multivariable models. Continued efforts will identify new genes that impact on radiosensitivity to generate new knowledge on toxicity patho-genesis and tests to incorporate into the clinical decision-making process.

UR - http://www.scopus.com/inward/record.url?scp=85053833312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053833312&partnerID=8YFLogxK

U2 - 10.1259/bjr.20170949

DO - 10.1259/bjr.20170949

M3 - Review article

C2 - 29888979

AN - SCOPUS:85053833312

VL - 91

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1091

M1 - 20170949

ER -